What's new

[PIO] Recommendation for EU approval of the first adapted booster vaccines against COVID-19

29839.jpg




The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of two vaccines tailored to provide broader protection against COVID-19 disease. Comirnaty Original/Omicron BA.1 vaccine and Spikevax Bivalent Original/Omicron BA.1 vaccine are intended for administration to persons aged 12 years and older who have received at least the original COVID-19 vaccination regimen. These vaccines are versions of the original Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) vaccines adapted to target, in addition to the original SARS-CoV-2 virus strain, the Omicron BA.1 sub-variant.

The vaccines are adapted (i.e. updated) to better address circulating SARS-CoV-2 virus variants. Adapted vaccines can broaden protection against different variants and are therefore expected to help maintain optimal protection against COVID-19 as the virus evolves.

Studies have shown that Comirnaty Original/Omicron BA.1 and Spikevax Bivalent Original/Omicron BA.1 can elicit strong immune responses against the Omicron BA.1 sub variant and the original SARS-CoV-2 strain in previously vaccinated individuals. In particular, they were most effective in triggering immune responses against the BA.1 sub variant than the original vaccines.

The adverse reactions observed with the adapted vaccines were comparable to those observed with the originals and were typically mild and of short duration.

The two CHMP opinions will now be sent to the European Commission, which will adopt a final decision.

As the pandemic evolves, the EU strategy is to have a wide range of tailored vaccines targeting different variants against SARS-CoV-2 so that Member States have multiple options to meet their needs when planning their vaccination strategies. This is a key element of the overall strategy to combat the pandemic, as it is not possible to predict how the virus will evolve in the future and which variants will be released this winter. Other adapted vaccines incorporating different variants, such as the Omicron BA.4 and BA.5 sub-variants, are currently being considered by the EMA or will be submitted shortly and, if approved, will further expand the arsenal of available vaccines. The clinical data derived from the prototypes/BA.1 currently available will support the evaluation and approval of further adapted vaccines.

The prototype vaccines, Comirnaty and Spikevax, continue to be effective in preventing severe disease, hospitalisation and death associated with COVID-19 and will continue to be used in the context of vaccination campaigns in the EU, in particular for the initial vaccination regimen.

National authorities in EU Member States will determine who should receive which vaccines and when, taking into account factors such as infection and hospitalisation rates, risk to vulnerable groups, vaccine coverage and vaccine availability.

Evidence supporting the use of Comirnaty Original/Omicron BA.1

Comirnaty Original/Omicron BA.1 vaccine can be administered to people aged 12 years and older at least 3 months after the last dose of a COVID-19 vaccine.

The CHMP opinion on Comirnaty Original/Omicron BA.1 vaccine is based on 2 studies. The first study involving adults over 55 years of age who had previously received 3 doses of Comirnaty (initial vaccination regimen and booster dose) found that the immune response to the Omicron BA.1 sub-variant was higher after a second booster dose of Comirnaty Original/Omicron BA.1 vaccine compared to the immune response after a second booster dose of Comirnaty Original (measured by the level of antibodies to the Omicron BA.1 sub-variant). In addition, the immune response to the original SARS-CoV-2 virus strain was comparable for both vaccines. The study enrolled more than 1,800 subjects, of whom approximately 300 received the Comirnaty Original/Omicron BA.1 vaccine in its final formulation.

Further data from a study involving more than 600 subjects aged between 18 and 55 years who had previously received 3 doses of Comirnaty showed that the immune response to the Omicron BA.1 sub variant was higher in subjects who received a booster dose with a vaccine containing only the Omicron BA.1 component compared to those who received a booster dose with the original Comirnaty vaccine.

Based on these data, it was concluded that the immune response to the Omicron BA.1 subtype after booster dosing with Comirnaty Original/Omicron BA.1 vaccine in subjects aged 18 to 55 years would be at least equal to that in subjects aged over 55 years. In addition, based on previous data in younger individuals, it is also concluded that the immune response to a booster dose with Comirnaty Original/Omicron BA.1 vaccine in adolescents would be at least equal to that in adults.

Evidence supporting the use of Spikevax Bivalent Original/Omicron BA.1

Spikevax Bivalent Original/Omicron BA.1 vaccine can be administered to adults and adolescents from the age of 12 years, at least 3 months after the initial vaccination regimen or a booster dose with COVID-19 vaccine. The CHMP opinion on Spikevax Bivalent Original/Omicron BA.1 vaccine is based on data from a study involving more than 800 adults aged 18 years and older. The study found that a booster dose of the Spikevax Bivalent Original/Omicron BA.1 bivalent vaccine induced a stronger immune response against the SARS-CoV-2 strain and the Omicron BA.1 subtype compared to a booster dose of the original Spikevax vaccine. The study compared antibody levels in subjects previously vaccinated with an initial vaccination regimen and a booster dose of Spikevax and given a second booster dose of either Spikevax or Spikevax Bivalent Original/Omicron BA.1. It was also concluded that Spikevax Bivalent Original/Omicron BA.1 could be used as a first booster after the initial vaccination and that the immune response induced by a booster dose with Spikevax Bivalent Original/Omicron vaccine in adolescents aged 12-17 years would be at least equal to that in adults, since previous data with Spikevax have shown a comparable effect.

How the adapted vaccines work

The adapted vaccines work in the same way as the original vaccines.

Both adapted vaccines work by preparing the body to defend itself against COVID-19. Each vaccine contains molecules called mRNAs that are instructed to produce spike proteins of the original SARS-CoV-2 virus and the Omicron BA.1 sub variant. The spike protein is a protein on the surface of the virus that the virus needs to enter the cells of the body and may differ between virus variants. By tailoring the vaccines, the goal is to broaden protection against different variants.

When a person is given one of these vaccines, some of their cells will read the mRNA instructions and temporarily produce the spike proteins. The person's immune system will then recognise these proteins as foreign and activate natural defences - antibodies and T cells - against them.

If, later, the vaccinated person comes into contact with the virus, the immune system will recognise the spike protein on its surface and be ready to defend itself. The immune system's antibodies and cells can protect against COVID-19 disease by killing the virus through synergy, preventing it from entering the body's cells and destroying infected cells.

The mRNA molecules from the vaccines do not remain in the body but break down shortly after vaccination.

More about the procedures

The companies responsible for marketing the Spikevax vaccine and the Comirnaty vaccine have submitted applications (also known as variation applications) to vary the existing marketing authorisations of the approved Comirnaty and Spikevax vaccines to include the use of the adapted vaccines. These applications included data on the quality and safety of the adapted vaccines and their ability to trigger immune responses against various strains of SARS-CoV-2 virus.

The review was conducted by the EMA's Committee for Medicinal Products for Human Use (CHMP), which is responsible for questions on medicinal products for human use. The opinion of the CHMP has been forwarded to the European Commission, which will adopt a final legally binding decision applicable in all EU Member States.

(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO

Source

 
Back
Top